Liver Neoplasms Clinical Trial
Official title:
Randomised Double Blind Controlled Study of the Effectiveness of Paravertebral Nerve Block in Decreasing Analgesia Requirements and Improving Patient Experience During Interventional Hepatic Procedures.
Verified date | March 2016 |
Source | McGill University Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
This study is aimed at assessing whether performing a paravertebral block (a type of regional pain relief) can reduce the pain and anxiety patients experience during radiological procedures on the liver.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 95 Years |
Eligibility |
Inclusion Criteria: - Male or non-pregnant female subjects, between the ages of 18 and 80 at the time of enrollment. Subjects referred for liver/biliary interventions to the angiography department. Written informed consent to participate in the study. Ability to comply with the requirements of the study procedures Exclusion Criteria: - Subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment. Subjects with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study. Patients will only be excluded on this basis following discussion with another interventional radiologist. Subjects who are uncooperative or cannot follow instructions. Mental state that may preclude completion of the study procedure or ability to obtain informed consent. Pregnant or nursing female subjects. Patient who are to undergo liver biopsy or routine biliary tube exchange. Patients with neurological/spinal conditions, or a BMI over 40, that would prevent safe/effective or well-targeted paravertebral blockade. Patient unable to tolerate the paravertebral block procedure, for example due to inability to lie prone |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Montreal General Hospital | Montreal | Quebec |
Canada | Royal Victoria Hospital | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Richard Lindsay |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose of intravenous sedation required during and after the procedure | 1 hour | No | |
Secondary | Improvement in analogue pain scoring after the procedure | 1 hour | No | |
Secondary | Procedure duration | 1 hour | No | |
Secondary | Complication rate of liver procedure | 24 hours | Yes | |
Secondary | Complication rate of paravertebral block | 1 hour | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
Not yet recruiting |
NCT03592550 -
The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
|
||
Not yet recruiting |
NCT02521129 -
A New Track Ablation Device for Liver Biopsy: A Feasibility Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02168608 -
Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
|
N/A | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Active, not recruiting |
NCT01177007 -
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
|
Phase 2 | |
Completed |
NCT00788697 -
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
|
Phase 3 | |
Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
Completed |
NCT00094003 -
Study of NS-9 in Patients With Liver Metastases
|
Phase 1 | |
Terminated |
NCT00051532 -
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT00001587 -
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
|
Phase 1 | |
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT03289273 -
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
|
||
Terminated |
NCT03349255 -
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03715517 -
Spinal Anesthesia For Enhanced Recovery After Liver Surgery
|
N/A | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01744054 -
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
|
Phase 1 | |
Active, not recruiting |
NCT02969096 -
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
|
Phase 2 |